A Phase IIa Randomized Control Trial of VEL015 ( Sodium Selenate) in Mild-Moderate Alzheimer's Disease
Charles B Malpas, Lucy Vivash, Sila Genc, Michael M Saling, Patricia Desmond, Christopher Steward, Rodney J Hicks, Jason Callahan, Amy Brodtmann, Steven Collins, Stephen Macfarlane, Niall M Corcoran, Christopher M Hovens, Dennis Velakoulis, Terence J O'Brien
Journal of Alzheimer's Disease | IOS PRESS | Published : 2016
The authors would like to thank the patients and their caregivers for participating in this study. We also thank the research staff at the various clinical sites: Anthony Ang, Jennifer Bortoli, Darren Germaine, Christopher Godden, Jack Germaine, Sean Hosking, Lucas Litewka, Elaine Lui, David Murphy, and Zofia Ross. Charles Malpas is the recipient of an Alzheimer's Australia Viertel Foundation postgraduate research scholarship.This study was funded by Velacor Therapeutics. The data were analyzed, and manuscript written, independently by the authors.